BLRX.TA - BioLineRx Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
321.80
-1.90 (-0.59%)
As of 9:54AM IDT. Market open.
Stock chart is not supported by your current browser
Previous Close323.70
Open323.60
Bid321.70 x 255900
Ask329.50 x 42900
Day's Range321.80 - 323.60
52 Week Range287.00 - 440.00
Volume7,487
Avg. Volume70,793
Market Cap347.647M
Beta0.11
PE Ratio (TTM)N/A
EPS (TTM)-0.25
Earnings DateMay 9, 2018 - May 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • Aclaris Stock Up on JAK Inhibitor's Encouraging Activity
    Zacks12 days ago

    Aclaris Stock Up on JAK Inhibitor's Encouraging Activity

    Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.

  • BioLineRx Sees Hammer Chart Pattern: Time to Buy?
    Zacks19 days ago

    BioLineRx Sees Hammer Chart Pattern: Time to Buy?

    BioLineRx Sees Hammer Chart Pattern: Time to Buy?

  • PR Newswirelast month

    BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients

    TEL AVIV, Israel, June 18, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that new data presented at the 23rd Annual Congress of the European Hematology Association (EHA), held in Stockholm, Sweden, shows that BL-8040, combined with high dose cytarabine (HiDAC), significantly enhanced overall survival in difficult-to-treat relapsed or refractory AML (r/r AML) patients in a Phase 2a clinical trial.

  • PR Newswirelast month

    BioLineRx to Participate at JMP Securities 2018 Life Sciences Conference

    TEL AVIV, Israel , June 13, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...

  • PR Newswire2 months ago

    BioLineRx Reports First Quarter 2018 Financial Results

    TEL AVIV, Israel , May 22, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results ...

  • PR Newswire2 months ago

    BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation

    TEL AVIV, Israel, May 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive results from a Phase 2 clinical trial assessing BL-8040 as a single agent for hematopoietic stem cell mobilization in an allogeneic transplantation setting. Mobilization of hematopoietic stem and progenitor cells (HSPCs) for the purpose of donor (allogeneic) transplantation after high-dose chemotherapy is currently performed using a 4-5 day treatment cycle with G-CSF and a 1-2 day apheresis procedure. This proof-of-concept Phase 2 study, consisting of 24 donor/recipient pairs, assesses the ability of BL-8040 monotherapy to mobilize HSPCs for transplantation in a single administration.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Biolinerx Ltd/S ADR (NASDAQ: BLRX ) stock was trading ...

  • Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)
    Zacks3 months ago

    Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)

    Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)

  • PR Newswire4 months ago

    BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors

    TEL AVIV, Israel, March 26, 2018 /PRNewswire/ --  BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the use of AGI-134, a novel immunotherapy compound, for the treatment of solid cancer tumors. This patent, when issued, will be valid until May 2035 with a possibility of up to five years patent term extension. Additional corresponding patent applications for AGI-134 are pending in Europe, Japan, China, Canada, Australia and Israel.

  • PR Newswire4 months ago

    BioLineRx to Present at the 28th Annual Oppenheimer Healthcare Conference

    TEL AVIV, Israel , March 14, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...

  • PR Newswire4 months ago

    BioLineRx Reports Year End 2017 Financial Results

    TEL AVIV, Israel , March 6, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for ...

  • PR Newswire5 months ago

    BioLineRx to Report Annual 2017 Results on March 6, 2018

    Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel, Feb. 27, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on ...

  • PR Newswire5 months ago

    BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13

    TEL AVIV, Israel , Feb. 6, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...

  • BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa
    Zacks6 months ago

    BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa

    BioLineRx (BLRX) posts encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, assessing its lead pipeline candidate, BL-8040, for pancreatic cancer patients.

  • PR Newswire6 months ago

    BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer

    TEL AVIV, Israel, Jan. 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today partial results from the monotherapy portion of BL-8040's Phase 2a COMBAT study showing that BL-8040 increases infiltration of T cells into the tumor in patients with metastatic pancreatic cancer. The data will be presented as a poster titled "Evaluation of Pharmacodynamic Biomarkers in Patients with Metastatic Pancreatic Cancer Treated with BL-8040, a Novel CXCR4 Antagonist (Abstract 276)" at the ASCO 2018 Gastrointestinal Cancers Symposium, on January 19, 2018 in San Francisco, CA.

  • Stock Update (NASDAQ:BLRX): Bioline RX Ltd Sets in Motion Phase 3 Trial for Stem Cell Mobilization Therapy BL-8040
    SmarterAnalyst7 months ago

    Stock Update (NASDAQ:BLRX): Bioline RX Ltd Sets in Motion Phase 3 Trial for Stem Cell Mobilization Therapy BL-8040

    Bioline RX Ltd (NASDAQ:BLRX) is officially turning its Phase 3 GENESES clinical trial's wheels, with the Israeli drug maker revealing today the launch of evaluating its stem-cell mobilization asset BL-8040. In the initiation of the clinical trial, BiolineRx will be investigating the mobilization of hematopoietic stem cells by BL-8040 against a placebo, on top of granulocyte colony-stimulating factor (G-CSF), a powerful inducer of hematopoietic stem cell (HSC) mobilization from the bone marrow into the bloodstream.

  • PR Newswire7 months ago

    BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY

    TEL AVIV, Israel, Dec. 5, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today hosts its investor breakfast meeting at the Convene Conference Center near Grand Central in New York, NY. Philip Serlin, Chief Executive Officer of BioLineRx, stated, "This annual event gives us the opportunity to directly meet with our investors for updates on our progress:  steady advancements on our multiple clinical programs in stem cell mobilization, combination immunotherapies and acute myeloid leukemia (AML), as well as our new and novel immuno-oncology therapy.

  • PR Newswire8 months ago

    BioLineRx Reports Third Quarter 2017 Financial Results

    TEL AVIV, Israel , Nov. 21, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for ...

  • BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer
    Zacks9 months ago

    BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer

    BioLineRx (BLRX) and partner Genentech initiate a phase Ib/II study to evaluate the company's lead pipeline candidate, BL-8040, in combination with Tecentriq for treating gastric cancer.

  • BioLineRx Moves a Regulatory Submission for BL-8040 Trial
    Zacks11 months ago

    BioLineRx Moves a Regulatory Submission for BL-8040 Trial

    BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.

  • PR Newswire11 months ago

    BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization

    TEL AVIV, Israel, Aug 21, 2017 /PRNewswire/ --BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the filing of regulatory submissions required to commence a randomized, controlled Phase 3 registrational trial of BL-8040 for the mobilization of hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. The trial, named GENESIS, is expected to commence by the end of 2017, following receipt of regulatory approvals.

  • PR Newswire11 months ago

    BioLineRx Reports Second Quarter 2017 Financial Results

    TEL AVIV, Israel , Aug. 8, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for ...

  • BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session
    Zackslast year

    BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session

    BioLine Rx Ltd (BLRX) shares rise over 5% in the last trading session.